Fundamental Data for MNTA

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.

# Employees: 167

Address: 675 West Kendall Street,Cambridge,MA,USA

Phone: 617 491-9700

Fax: 617-621-0431

Website: www.momentapharma.com

Email: info@momentapharma.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Peter Barrett (Chmn.; Dir.)

Craig A. Wheeler (Presi.; C.E.O.; Dir.)

Richard P. Shea (Sr. V.P.; C.F.O.)

John K. Clarke (Dir.)

Alan L. Crane (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/11/2010

Mean EPS (Next Qtr): ($0.35)

Mean EPS (Year): ($1.60)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 7

Shares Performance

Period	MNTA	Compare to S&P
YTD	-14.22 %	-29.02 %
4 Weeks	9.10 %	3.57 %
12 Weeks	2.79 %	-4.28 %

Shares Information

Analyst Coverage: Y

Avg Volume: 509468

Shares Outstanding: 43M

Market Cap: $0.44B

52 Week High: $12.49

52 Week Low: $7.12

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 MNTA split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 11.63 %

EPS Growth in Last Year: 15.56 %

Sales Growth in Last Quarter: -39.32 %

Sales Growth in Last Quarter: 2.40 %

Financials

Qtr Book Value: $4.11

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 24.890